Interaction Checker

Lanreotide interactions

Lanreotide (Somatuline Depot) has 68 documented interactions across the FDA labels and fact sheets we index: 2 major, 66 moderate, 0 minor, and 0 where a label reports no significant interaction. Each entry below quotes the sentence behind it. This drug page is a starting point, not a verdict for your situation.

Interactions from the label

Major interactions (2)

  • Dextromethorphan and quinidineserotonergic drugMajor

    Since it cannot be excluded that Lanreotide Injection may have this effect, avoid other drugs mainly metabolized by CYP3A4 and which have a low therapeutic index (e.g., quinidine, terfenadine). (Lanreotide label, Drug interactions)

  • QuinidineantiarrhythmicMajor

    Since it cannot be excluded that Lanreotide Injection may have this effect, avoid other drugs mainly metabolized by CYP3A4 and which have a low therapeutic index (e.g., quinidine, terfenadine). (Lanreotide label, Drug interactions)

Moderate interactions (66)

  • AcarboseantidiabeticModerate

    Hyperglycemia and Hypoglycemia : Glucose monitoring is recommended and antidiabetic treatment adjusted accordingly. (Lanreotide label, Warnings and precautions)

  • Acebutololbeta blockerModerate

    Bradycardia-Inducing Drugs (e.g., beta-blockers) : Lanreotide Injection may decrease heart rate. (Lanreotide label, Drug interactions)

  • AlogliptinDPP-4 inhibitorModerate

    Hyperglycemia and Hypoglycemia : Glucose monitoring is recommended and antidiabetic treatment adjusted accordingly. (Lanreotide label, Warnings and precautions)

  • Alogliptin and metforminDPP-4 inhibitorModerate

    Hyperglycemia and Hypoglycemia : Glucose monitoring is recommended and antidiabetic treatment adjusted accordingly. (Lanreotide label, Warnings and precautions)

  • Atenololbeta blockerModerate

    Bradycardia-Inducing Drugs (e.g., beta-blockers) : Lanreotide Injection may decrease heart rate. (Lanreotide label, Drug interactions)

  • Atenolol and chlorthalidonebeta blockerModerate

    Bradycardia-Inducing Drugs (e.g., beta-blockers) : Lanreotide Injection may decrease heart rate. (Lanreotide label, Drug interactions)

  • Betaxololbeta blockerModerate

    Bradycardia-Inducing Drugs (e.g., beta-blockers) : Lanreotide Injection may decrease heart rate. (Lanreotide label, Drug interactions)

  • BexagliflozinSGLT2 inhibitorModerate

    Hyperglycemia and Hypoglycemia : Glucose monitoring is recommended and antidiabetic treatment adjusted accordingly. (Lanreotide label, Warnings and precautions)

  • Bisoprololbeta blockerModerate

    Bradycardia-Inducing Drugs (e.g., beta-blockers) : Lanreotide Injection may decrease heart rate. (Lanreotide label, Drug interactions)

  • Bisoprolol and hydrochlorothiazidebeta blockerModerate

    Bradycardia-Inducing Drugs (e.g., beta-blockers) : Lanreotide Injection may decrease heart rate. (Lanreotide label, Drug interactions)

  • Brimonidine and timololalpha-adrenergic agonistModerate

    Bradycardia-Inducing Drugs (e.g., beta-blockers) : Lanreotide Injection may decrease heart rate. (Lanreotide label, Drug interactions)

  • Bromocriptinedopamine agonistModerate

    Bromocriptine : Lanreotide Injection may increase the absorption of bromocriptine. (Lanreotide label, Drug interactions)

  • CanagliflozinSGLT2 inhibitorModerate

    Hyperglycemia and Hypoglycemia : Glucose monitoring is recommended and antidiabetic treatment adjusted accordingly. (Lanreotide label, Warnings and precautions)

  • Carvedilolbeta blockerModerate

    Bradycardia-Inducing Drugs (e.g., beta-blockers) : Lanreotide Injection may decrease heart rate. (Lanreotide label, Drug interactions)

  • CyclosporineimmunosuppressantModerate

    Cyclosporine : Lanreotide Injection may decrease the absorption of cyclosporine. (Lanreotide label, Drug interactions)

  • DapagliflozinSGLT2 inhibitorModerate

    Hyperglycemia and Hypoglycemia : Glucose monitoring is recommended and antidiabetic treatment adjusted accordingly. (Lanreotide label, Warnings and precautions)

  • Dapagliflozin and metforminSGLT2 inhibitorModerate

    Hyperglycemia and Hypoglycemia : Glucose monitoring is recommended and antidiabetic treatment adjusted accordingly. (Lanreotide label, Warnings and precautions)

  • Dorzolamide and timololcarbonic anhydrase inhibitorModerate

    Bradycardia-Inducing Drugs (e.g., beta-blockers) : Lanreotide Injection may decrease heart rate. (Lanreotide label, Drug interactions)

  • DulaglutideGLP-1 receptor agonistModerate

    Hyperglycemia and Hypoglycemia : Glucose monitoring is recommended and antidiabetic treatment adjusted accordingly. (Lanreotide label, Warnings and precautions)

  • EmpagliflozinSGLT2 inhibitorModerate

    Hyperglycemia and Hypoglycemia : Glucose monitoring is recommended and antidiabetic treatment adjusted accordingly. (Lanreotide label, Warnings and precautions)

  • Empagliflozin and metforminSGLT2 inhibitorModerate

    Hyperglycemia and Hypoglycemia : Glucose monitoring is recommended and antidiabetic treatment adjusted accordingly. (Lanreotide label, Warnings and precautions)

  • Esmololbeta blockerModerate

    Bradycardia-Inducing Drugs (e.g., beta-blockers) : Lanreotide Injection may decrease heart rate. (Lanreotide label, Drug interactions)

  • ExenatideGLP-1 receptor agonistModerate

    Hyperglycemia and Hypoglycemia : Glucose monitoring is recommended and antidiabetic treatment adjusted accordingly. (Lanreotide label, Warnings and precautions)

  • GlimepiridesulfonylureaModerate

    Hyperglycemia and Hypoglycemia : Glucose monitoring is recommended and antidiabetic treatment adjusted accordingly. (Lanreotide label, Warnings and precautions)

  • GlipizidesulfonylureaModerate

    Hyperglycemia and Hypoglycemia : Glucose monitoring is recommended and antidiabetic treatment adjusted accordingly. (Lanreotide label, Warnings and precautions)

  • Glipizide and metforminsulfonylureaModerate

    Hyperglycemia and Hypoglycemia : Glucose monitoring is recommended and antidiabetic treatment adjusted accordingly. (Lanreotide label, Warnings and precautions)

  • GlucagonModerate

    Hyperglycemia and Hypoglycemia Pharmacological studies in animals and humans show that lanreotide, like somatostatin and other somatostatin analogs, inhibits the secretion of insulin and glucagon. (Lanreotide label, Warnings and precautions)

  • GlyburidesulfonylureaModerate

    Hyperglycemia and Hypoglycemia : Glucose monitoring is recommended and antidiabetic treatment adjusted accordingly. (Lanreotide label, Warnings and precautions)

  • Glyburide and metforminsulfonylureaModerate

    Hyperglycemia and Hypoglycemia : Glucose monitoring is recommended and antidiabetic treatment adjusted accordingly. (Lanreotide label, Warnings and precautions)

  • Insulin aspartinsulinModerate

    Hyperglycemia and Hypoglycemia : Glucose monitoring is recommended and antidiabetic treatment adjusted accordingly. (Lanreotide label, Warnings and precautions)

  • Insulin degludecinsulinModerate

    Hyperglycemia and Hypoglycemia : Glucose monitoring is recommended and antidiabetic treatment adjusted accordingly. (Lanreotide label, Warnings and precautions)

  • Insulin detemirinsulinModerate

    Hyperglycemia and Hypoglycemia : Glucose monitoring is recommended and antidiabetic treatment adjusted accordingly. (Lanreotide label, Warnings and precautions)

  • Insulin glargineinsulinModerate

    Hyperglycemia and Hypoglycemia : Glucose monitoring is recommended and antidiabetic treatment adjusted accordingly. (Lanreotide label, Warnings and precautions)

  • Insulin lisproinsulinModerate

    Hyperglycemia and Hypoglycemia : Glucose monitoring is recommended and antidiabetic treatment adjusted accordingly. (Lanreotide label, Warnings and precautions)

  • Insulin regular (human)insulinModerate

    Hyperglycemia and Hypoglycemia : Glucose monitoring is recommended and antidiabetic treatment adjusted accordingly. (Lanreotide label, Warnings and precautions)

  • Labetalolbeta blockerModerate

    Bradycardia-Inducing Drugs (e.g., beta-blockers) : Lanreotide Injection may decrease heart rate. (Lanreotide label, Drug interactions)

  • Levothyroxinethyroid hormoneModerate

    Thyroid Function Abnormalities : Decreases in thyroid function may occur; perform tests where clinically indicated. (Lanreotide label, Warnings and precautions)

  • Levothyroxine and liothyroninethyroid hormoneModerate

    Thyroid Function Abnormalities : Decreases in thyroid function may occur; perform tests where clinically indicated. (Lanreotide label, Warnings and precautions)

  • LinagliptinDPP-4 inhibitorModerate

    Hyperglycemia and Hypoglycemia : Glucose monitoring is recommended and antidiabetic treatment adjusted accordingly. (Lanreotide label, Warnings and precautions)

  • Linagliptin and metforminDPP-4 inhibitorModerate

    Hyperglycemia and Hypoglycemia : Glucose monitoring is recommended and antidiabetic treatment adjusted accordingly. (Lanreotide label, Warnings and precautions)

  • Liothyroninethyroid hormoneModerate

    Thyroid Function Abnormalities : Decreases in thyroid function may occur; perform tests where clinically indicated. (Lanreotide label, Warnings and precautions)

  • LiraglutideGLP-1 receptor agonistModerate

    Hyperglycemia and Hypoglycemia : Glucose monitoring is recommended and antidiabetic treatment adjusted accordingly. (Lanreotide label, Warnings and precautions)

  • MetforminbiguanideModerate

    Hyperglycemia and Hypoglycemia : Glucose monitoring is recommended and antidiabetic treatment adjusted accordingly. (Lanreotide label, Warnings and precautions)

  • Methimazoleantithyroid drugModerate

    Thyroid Function Abnormalities : Decreases in thyroid function may occur; perform tests where clinically indicated. (Lanreotide label, Warnings and precautions)

  • Metoprololbeta blockerModerate

    Bradycardia-Inducing Drugs (e.g., beta-blockers) : Lanreotide Injection may decrease heart rate. (Lanreotide label, Drug interactions)

  • Metoprolol and hydrochlorothiazidebeta blockerModerate

    Bradycardia-Inducing Drugs (e.g., beta-blockers) : Lanreotide Injection may decrease heart rate. (Lanreotide label, Drug interactions)

  • MiglitolantidiabeticModerate

    Hyperglycemia and Hypoglycemia : Glucose monitoring is recommended and antidiabetic treatment adjusted accordingly. (Lanreotide label, Warnings and precautions)

  • Nadololbeta blockerModerate

    Bradycardia-Inducing Drugs (e.g., beta-blockers) : Lanreotide Injection may decrease heart rate. (Lanreotide label, Drug interactions)

  • NateglinidemeglitinideModerate

    Hyperglycemia and Hypoglycemia : Glucose monitoring is recommended and antidiabetic treatment adjusted accordingly. (Lanreotide label, Warnings and precautions)

  • Nebivololbeta blockerModerate

    Bradycardia-Inducing Drugs (e.g., beta-blockers) : Lanreotide Injection may decrease heart rate. (Lanreotide label, Drug interactions)

  • Pindololbeta blockerModerate

    Bradycardia-Inducing Drugs (e.g., beta-blockers) : Lanreotide Injection may decrease heart rate. (Lanreotide label, Drug interactions)

  • PioglitazonethiazolidinedioneModerate

    Hyperglycemia and Hypoglycemia : Glucose monitoring is recommended and antidiabetic treatment adjusted accordingly. (Lanreotide label, Warnings and precautions)

  • Pioglitazone and glimepiridethiazolidinedioneModerate

    Hyperglycemia and Hypoglycemia : Glucose monitoring is recommended and antidiabetic treatment adjusted accordingly. (Lanreotide label, Warnings and precautions)

  • Pioglitazone and metforminthiazolidinedioneModerate

    Hyperglycemia and Hypoglycemia : Glucose monitoring is recommended and antidiabetic treatment adjusted accordingly. (Lanreotide label, Warnings and precautions)

  • Propranololbeta blockerModerate

    Bradycardia-Inducing Drugs (e.g., beta-blockers) : Lanreotide Injection may decrease heart rate. (Lanreotide label, Drug interactions)

  • Propylthiouracilantithyroid drugModerate

    Thyroid Function Abnormalities : Decreases in thyroid function may occur; perform tests where clinically indicated. (Lanreotide label, Warnings and precautions)

  • RepaglinidemeglitinideModerate

    Hyperglycemia and Hypoglycemia : Glucose monitoring is recommended and antidiabetic treatment adjusted accordingly. (Lanreotide label, Warnings and precautions)

  • SaxagliptinDPP-4 inhibitorModerate

    Hyperglycemia and Hypoglycemia : Glucose monitoring is recommended and antidiabetic treatment adjusted accordingly. (Lanreotide label, Warnings and precautions)

  • Saxagliptin and metforminDPP-4 inhibitorModerate

    Hyperglycemia and Hypoglycemia : Glucose monitoring is recommended and antidiabetic treatment adjusted accordingly. (Lanreotide label, Warnings and precautions)

  • SemaglutideGLP-1 receptor agonistModerate

    Hyperglycemia and Hypoglycemia : Glucose monitoring is recommended and antidiabetic treatment adjusted accordingly. (Lanreotide label, Warnings and precautions)

  • SitagliptinDPP-4 inhibitorModerate

    Hyperglycemia and Hypoglycemia : Glucose monitoring is recommended and antidiabetic treatment adjusted accordingly. (Lanreotide label, Warnings and precautions)

  • Sitagliptin and metforminDPP-4 inhibitorModerate

    Hyperglycemia and Hypoglycemia : Glucose monitoring is recommended and antidiabetic treatment adjusted accordingly. (Lanreotide label, Warnings and precautions)

  • Sotalolbeta blockerModerate

    Bradycardia-Inducing Drugs (e.g., beta-blockers) : Lanreotide Injection may decrease heart rate. (Lanreotide label, Drug interactions)

  • Teriparatidethyroid hormoneModerate

    Thyroid Function Abnormalities : Decreases in thyroid function may occur; perform tests where clinically indicated. (Lanreotide label, Warnings and precautions)

  • Timololbeta blockerModerate

    Bradycardia-Inducing Drugs (e.g., beta-blockers) : Lanreotide Injection may decrease heart rate. (Lanreotide label, Drug interactions)

  • TirzepatideGLP-1 receptor agonistModerate

    Hyperglycemia and Hypoglycemia : Glucose monitoring is recommended and antidiabetic treatment adjusted accordingly. (Lanreotide label, Warnings and precautions)

Check Lanreotide against everything you take. Add your full list; every pair is checked at once.

Open in the checker

Not medical advice. Severity reflects the label's wording, not your circumstances. A "major" flag can be routine under supervision and a "minor" one can matter at high doses. Ask a pharmacist.